100 related articles for article (PubMed ID: 15103042)
1. Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Degner F; Lesaffre E; Zeidler H
Rheumatology (Oxford); 2004 May; 43(5):680-1; author reply 681-2. PubMed ID: 15103042
[No Abstract] [Full Text] [Related]
2. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
5. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
MacDonald TM; Morant SV; Goldstein JL; Burke TA; Pettitt D
Gut; 2003 Sep; 52(9):1265-70. PubMed ID: 12912856
[TBL] [Abstract][Full Text] [Related]
6. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
Karakaya G; Kalyoncu AF
Allergol Immunopathol (Madr); 2000; 28(6):319-21. PubMed ID: 11269899
[TBL] [Abstract][Full Text] [Related]
7. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.
Martin RM; Biswas P; Mann RD
Br J Clin Pharmacol; 2000 Jul; 50(1):35-42. PubMed ID: 10886116
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal complications and meloxicam.
Fenn GC; Morant SV; Shield MJ
Br J Rheumatol; 1997 Nov; 36(11):1234. PubMed ID: 9402874
[No Abstract] [Full Text] [Related]
10. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
Layton D; Heeley E; Shakir SA
J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
12. Rofecoxib and the risk of adverse upper gastrointestinal effects.
Whitney E
JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789660
[No Abstract] [Full Text] [Related]
13. Meloxicam--a safer NSAID?
Drug Ther Bull; 1998 Aug; 36(8):62-4. PubMed ID: 9876404
[No Abstract] [Full Text] [Related]
14. Safety of meloxicam: a global analysis of clinical trials [British Journal of Rheumatology, 1996;35(suppl. 1):68-77].
Fenn GC; Morant SV
Br J Rheumatol; 1997 Jul; 36(7):817-9. PubMed ID: 9255122
[No Abstract] [Full Text] [Related]
15. Rofecoxib and the risk of adverse upper gastrointestinal effects.
Freston J
JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789659
[No Abstract] [Full Text] [Related]
16. [Observations on the side effects after application of non-steroidal anti-inflammatory agents in dogs].
Gassner G; Stephan I; Schütt-Mast I
Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Apr; 26(2):119-23. PubMed ID: 9587983
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Houben JJ; Liem B
Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2338. PubMed ID: 10589225
[No Abstract] [Full Text] [Related]
18. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
MacDonald TM; Pettitt D; Lee FH; Schwartz JS
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii3-10. PubMed ID: 14585912
[TBL] [Abstract][Full Text] [Related]
19. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
Singh G; Lanes S; Triadafilopoulos G
Am J Med; 2004 Jul; 117(2):100-6. PubMed ID: 15234645
[TBL] [Abstract][Full Text] [Related]
20. Is rofecoxib safer than naproxen?
Adelman A
J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
